Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of vitamin A, vitamin D, zinc, and iron is a multi-ingredient micronutrient therapy being investigated by the First Hospital of Jilin University for the management of neurodevelopmental and behavioral disorders. This intervention is based on clinical evidence suggesting that children with conditions such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) often exhibit significant deficiencies in these specific vitamins and minerals. Vitamin A and Vitamin D function as ligands for nuclear receptors that regulate gene expression essential for neurogenesis, synaptic plasticity, and immune modulation. Zinc and iron serve as critical enzymatic cofactors for the synthesis of key neurotransmitters, including dopamine and serotonin, and are vital for myelination and overall brain development. The therapeutic goal of this combination is to address nutritional gaps and potentially improve core behavioral symptoms and cognitive outcomes in pediatric populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitamin A + vitamin D + zinc + iron.